

Mary A Allen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1515449/publications.pdf>

Version: 2024-02-01

33
papers

1,622
citations

361045

20
h-index

414034

32
g-index

33
all docs

33
docs citations

33
times ranked

2113
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of the HIV Vaccine Trials Network 702 Phase 2bâ€“3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk. <i>Journal of Infectious Diseases</i> , 2022, 226, 246-257.	1.9	11
2	Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120â€“MF59 in Adults. <i>New England Journal of Medicine</i> , 2021, 384, 1089-1100.	13.9	144
3	A retrospective analysis of incident pregnancy in phase 1 and 2a HIV-1 vaccine study participants does not support concern for adverse pregnancy or birth outcomes. <i>BMC Infectious Diseases</i> , 2021, 21, 802.	1.3	0
4	Benign ethnic neutropenia in a South African population, and its association with HIV acquisition and adverse event reporting in an HIV vaccine clinical trial. <i>PLoS ONE</i> , 2021, 16, e0241708.	1.1	2
5	Long-term mucosal T cell activation and homing phenotypes in recipients of an Ad5-vectorized HIV vaccine. <i>Vaccine</i> , 2020, 38, 5814-5821.	1.7	3
6	Social Impacts Among Participants in HIV Vaccine Trial Network (HVTN) Preventive HIV Vaccine Trials. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 488-496.	0.9	3
7	Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. <i>PLoS Medicine</i> , 2020, 17, e1003038.	3.9	27
8	HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens. <i>Scientific Reports</i> , 2020, 10, 2093.	1.6	17
9	Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. <i>PLoS Medicine</i> , 2020, 17, e1003117.	3.9	8
10	Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial. <i>Lancet HIV</i> , 2019, 6, e737-e749.	2.1	43
11	Antigenic competition in CD4 ⁺ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	18
12	Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial. <i>PLoS ONE</i> , 2018, 13, e0202753.	1.1	39
13	Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. <i>Lancet HIV</i> , 2018, 5, e366-e378.	2.1	86
14	DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8 ⁺ T-Cell Responses by Interleukin-12 Plasmid DNA. <i>Vaccine Journal</i> , 2017, 24, .	3.2	33
15	Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. <i>PLoS Medicine</i> , 2017, 14, e1002435.	3.9	104
16	Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants. <i>PLoS ONE</i> , 2016, 11, e0161753.	1.1	16
17	First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090). <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv082.	0.4	58
18	HIV vaccine-induced sero-reactivity: A challenge for trial participants, researchers, and physicians. <i>Vaccine</i> , 2015, 33, 1243-1249.	1.7	32

#	ARTICLE	IF	CITATIONS
19	Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men. <i>PLoS ONE</i> , 2015, 10, e0137666.	1.1	30
20	Phase I/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime/LIPO-5 Boost in Healthy, HIV-1-Uninfected Adult Participants. <i>Vaccine Journal</i> , 2014, 21, 1589-1599.	3.2	10
21	Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 388-396.	4.6	108
22	Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for Delivery. <i>Journal of Infectious Diseases</i> , 2013, 208, 818-829.	1.9	171
23	Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 507-515.	4.6	330
24	Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. <i>Vaccine</i> , 2009, 27, 243-249.	1.7	55
25	Social impact of preventive HIV vaccine clinical trial participation: A model of prevention, assessment and intervention. <i>Social Science and Medicine</i> , 2008, 66, 945-951.	1.8	27
26	Lessons From a Multisite International Trial in the Caribbean and South America of an HIV-1 Canarypox Vaccine (ALVAC-HIV vCP1452) With or Without Boosting With MN rgp120. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 46, 222-230.	0.9	29
27	Current advances and challenges in HIV-1 vaccines. <i>Current HIV/AIDS Reports</i> , 2006, 3, 39-47.	1.1	12
28	High-Dose Recombinant Canarypox Vaccine Expressing HIV-1 Protein, in Seronegative Human Subjects. <i>Journal of Infectious Diseases</i> , 2005, 192, 1249-1259.	1.9	66
29	Assessing the Attitudes, Knowledge, and Awareness of HIV Vaccine Research Among Adults in the United States. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 40, 617-624.	0.9	40
30	Current advances in HIV vaccines. <i>Current HIV/AIDS Reports</i> , 2004, 1, 18-24.	1.1	9
31	Human Immunodeficiency Virus (HIV) Seropositivity among Uninfected HIV Vaccine Recipients. <i>Journal of Infectious Diseases</i> , 2003, 187, 879-886.	1.9	42
32	HIV vaccines: Biological and clinical considerations. <i>Current Infectious Disease Reports</i> , 2002, 4, 359-368.	1.3	2
33	Trial-Related Discrimination in HIV Vaccine Clinical Trials. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 667-674.	0.5	47